Equities research analysts at StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Free Report) in a report issued on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Bellerophon Therapeutics Stock Performance
Shares of Bellerophon Therapeutics stock opened at $0.04 on Friday. Bellerophon Therapeutics has a twelve month low of $0.03 and a twelve month high of $0.42. The stock has a market cap of $440,388.00, a price-to-earnings ratio of -0.04 and a beta of 0.70. The company has a fifty day moving average price of $0.04 and a 200 day moving average price of $0.05.
About Bellerophon Therapeutics
Further Reading
- Five stocks we like better than Bellerophon Therapeutics
- Consumer Staples Stocks, Explained
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Why Are Stock Sectors Important to Successful Investing?
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.